Pricing Log in Create free account
Friday 6 November 2026 Export IMNM’s income statement to Excel — free account

Immunome, Inc.

IMNM Healthcare Biotechnology

Immunome, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $6.9 million, down 23.2% from fiscal 2024.

Revenue
+69.8%
EPS
−30.0%
Free cash flow
−27.0%

Quarter to June 2026, against a year earlier

18.58 0.67 +3.74%
Market cap
$2.1B
P/E
0.0×
Fwd P/E
−7.6×
Dividend yield
—
F-score
4/9
Altman Z
21.57
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Immunome, Inc. (IMNM) Revenue

Alert me on Revenue

Immunome, Inc.'s revenue for fiscal 2025 was $6.9M, down 23.2% from $9.0M in fiscal 2024. Immunome, Inc. ranks 201st of 390 Biotechnology companies by revenue.

Revenue, annual

Embed this chart

Annual newest first

Period Revenue Change
FY2025 $6.9M (23.23%)
FY2024 $9.0M (35.50%)
FY2023 $14.0M —

Quarterly newest first

Period Revenue Change
Jun 2025 $4.0M 37.22%
Mar 2025 $2.9M 6.87%
Dec 2024 $2.7M (5.91%)
Sep 2024 $2.9M 23.10%
6 more quarters

Revenue against peers

Company Revenue
BHVN Biohaven Ltd. compare $995.4M
ADMA ADMA Biologics Inc compare $519.2M
VCEL Vericel Corporation compare $324.2M
AUPH Aurinia Pharmaceuticals Inc compare $321.7M
LKFT Lakefront Biotherapeutics - Sponsored ADR compare $282.0M
PVLA Palvella Therapeutics, Inc. compare $41.6M
IMNM Immunome, Inc. $12.6M
CLDX Celldex Therapeutics, Inc. compare $887.0K
VERA Vera Therapeutics, Inc. compare —

What Revenue is

Revenue tells an investor how much a company brought in from selling its goods and services over a period, before any costs are taken out.

Reported line item

The full definition of Revenue →

More on IMNM